Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial

The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. Based on EURTAC and several Asian trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Benlloch, Susana, Botero, Maria Luisa, Beltran-Alamillo, Jordi, Mayo, Clara, Gimenez-Capitán, Ana, de Aguirre, Itziar, Queralt, Cristina, Ramirez, Jose Luis, Cajal, Santiago Ramón y., Klughammer, Barbara, Schlegel, Mariette, Bordogna, Walter, Chen, David, Zhang, Guili, Kovach, Barbara, Shieh, Felice, Palma, John F., Wu, Lin, Lawrence, H. Jeffrey, Taron, Miquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934888/
https://www.ncbi.nlm.nih.gov/pubmed/24586842
http://dx.doi.org/10.1371/journal.pone.0089518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934888/
https://www.ncbi.nlm.nih.gov/pubmed/24586842
http://dx.doi.org/10.1371/journal.pone.0089518

Ejemplares similares